



# Nanomedicines ALLIANCE NanoMed Digest

Join the Nanomedicines Alliance. Contact us at [info@nanomedicines-alliance.org](mailto:info@nanomedicines-alliance.org).

## Legislative and Regulatory Highlights

### ECHA Guidance for Nanomaterials

The European Chemicals Agency has [published REACH guidance](#) to assist registrants in preparing dossiers that cover nanoforms before the 2018 registration deadline. The new guidance documents advise registrants on how to justify the use of hazard data between nanoforms (and the non-nanoforms) and within groups of nanoforms of the same substance, as well as giving recommendations for distinguishing between different nanoforms of a substance and how to report information on nanoforms consistently in the dossiers. ECHA has also updated existing guidance on nanomaterials to help registrants meet the information requirements for REACH regulation.

### Iran – China Center for Research and Development

Iran and China have [partnered to open a nanotechnology laboratory](#) for students in Guangzhou, China with Iranian equipment. The Center is intended to be a foundation for mutual collaboration in medical engineering, conducting joint scientific and technological workshops, participating in market-oriented joint research, and student and research transfer programs.

### Health Canada Nanoscale Prioritization

Health Canada and Environment and Climate Change Canada are in the midst of [prioritizing nanoscale forms of substances](#) on the Domestic Substances List. Results of the prioritization process are expected to be available in the first half of 2018. The goal of this initiative is to identify the potential risks to human health and the environment that may be posed by nanomaterials in commerce in Canada. The government also anticipates constructing a scientific risk assessment framework for nanomaterials.

## Business News

[Nanobiotix](#) is presented at the American Association for Cancer Research meeting on preclinical data of NBTXR3. The data support the antitumor efficacy of the treatment in *in vitro* and *in vivo* studies.

[Almirall](#) is collaborating with the Institute of Material Science from Barcelona on testing new dermatological treatment formulations containing nanomedicines. The collaboration aims to treat inflammatory skin conditions.

[Takeda and BioSurfaces Inc.](#) have announced a joint research program utilizing BioSurfaces' nanomaterial technology to develop medical device treatments for patients with gastrointestinal diseases.

[Parvus Therapeutics](#) has announced a collaboration granting Novartis exclusive, worldwide rights to Parvus' nanomedicines treatment for Type 1 diabetes.

## Conferences and Workshops

[International Conference on Nanomedicine and Nanobiotechnology](#), 25 – 27 September 2017, Barcelona, Spain

[NanoBioMed 2017](#), 22 – 24 November 2017, Barcelona, Spain

[Nanomedicine and Nanotechnology in Health Care](#), 23 – 24 November 2017, Melbourne, Australia

## Reference Section

### Nano Organizations

[National Center for Toxicological Research](#) (NCTR)

[National Nanotechnology Initiative](#) (NNI)

[Nano Science and Technology Consortium](#) (NSTC)

[Nano Science and Technology Institute](#) (NSTI)

[The Nanotechnology Institute](#) (NTI)

### Nano Journals

[American Chemical Society -- Nano Letters](#)

[Institute of Physics – Nanotechnology](#)

[NanoTrends - A Journal of Nanotechnology and its Applications](#)

[BCC Research -- Nanotechnology Reports](#)

[Nanomedicine: Nanotechnology, Biology, and Medicine](#)

[Nature Nanotechnology](#)

## Contact

For further information, or if you have any questions about the Nanomedicines Alliance, please contact the Nanomedicines Alliance Secretariat at [info@nanomedicines-alliance.org](mailto:info@nanomedicines-alliance.org).

---

This newsletter is provided as a public service and resource to the scientific and regulatory community interested in nanomedicines. The mention of any organizations, conferences or other events in this newsletter IS FOR INFORMATIONAL PURPOSES ONLY and does not represent an endorsement by the Nanomedicines Alliance or any of its members.